November is a time to raise awareness and show support for the more than 6.2 million Americans living with Alzheimer's ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is gearing up to showcase critical research at the 17th Clinical Trials on ...

A study of cells from 84 cadaver brains suggests that Alzheimer’s has two distinct phases, and that one type of neuron is ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Baseline characteristics of the 130 participants enrolled in the study, as described in the poster: “DLB is one of the most common forms of dementia and a complex neurological condition. Symptoms ...

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease ...

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. That’s why scientists search for therapies ...

Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Al ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Two posters were presented by Annovis' President and CEO, Dr. Maria Maccecchini, focusing on the company's lead drug candidate bunta ...